


Checkpoint Inhibition

Rapid Development Across Multiple Tumor Types

- Checkpoint inhibitors are already approved in five tumor types globally, although status varies by geography
- Regulatory submissions are under review in one other tumor type (SCCHN)
- Phase III trials are ongoing with 7 agents in this class across 14 tumor types
- Scores of other indications being explored in Phase I and II



Source: www.clinicaltrials.gov, Industry- or cooperative group-sponsored development, as of July 13, 2016.